SCHEMBL26016355

SCHEMBL26016355

C#Cc1ccc(CC(C)(C)C)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.35
PGR P06401 1/20 0.35
NR3C2 P08235 1/20 0.35
PYCR1 P32322 1/20 0.33
FFAR1 O14842 10/20 0.33
FFAR4 Q5NUL3 8/20 0.33
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
GABRA4 P48169 1/20 0.32
GABRE P78334 1/20 0.32
GABRA6 Q16445 1/20 0.32
GABRG1 Q8N1C3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13315163 0.82 NR3C1 (0.48) NR3C1PGRNR3C2FFAR1FFAR4
SCHEMBL15491228 0.79 FFAR1 (0.38) PYCR1FFAR1FFAR4GABRA1GABRA5
SCHEMBL26016357 0.79 PYCR1 (0.35) NR3C1PGRNR3C2PYCR1GABRP
SCHEMBL1164992 0.76 FFAR1 (0.38) PYCR1FFAR1FFAR4MAP2K2MAP2K1
SCHEMBL24837945 0.76 LOXL2 (0.38) PYCR1FFAR1FFAR4MAP2K2MAP2K1
SCHEMBL11229826 0.75 GABRA1 (0.33) PYCR1FFAR1FFAR4GABRA1GABRB2
SCHEMBL16286817 0.75 PARP1 (0.36) PYCR1FFAR1MAP2K2MAP2K1
SCHEMBL1704764 0.75 IDO1 (0.48) NR3C1PGRNR3C2
SCHEMBL17726213 0.73 ADRA2B (0.45)
SCHEMBL855374 0.73 TAAR1 (0.35) FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof JAK2, JAK1, JAK3 NR3C1 898/4885PGR 1300/4885NR3C2 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.